TY  - JOUR
AU  - Radojević-Škodrić, Sanja
AU  - Brašanac, Dimitrije
AU  - Đuričić, Slaviša M.
AU  - Glumac, Sofija
AU  - Lončar, Zlatibor
AU  - Pavlović, Ivan
AU  - Todorović, Ana
AU  - Nikolić, Gorana V.
AU  - Baralić, Ivana
AU  - Pejić, Snežana
PY  - 2019
UR  - https://peerj.com/articles/6212
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8025
AB  - Background: Cyclin A overexpression is found in a variety of human tumors and correlates with unfavorable outcome. We analyzed immunohistochemical expression of cyclin A in Wilms tumor (WT) in relation to clinicopathological characteristics, preoperative chemotherapy (PrOpChTh), and overall survival (OS). Methods: This retrospective study involved 43 patients who underwent nephrectomy from January 1996 to October 2010. Tumor stage and histological subtype were determined by revised Societé International d’Oncologie Pediatrique protocol, based on histological components/alterations caused by PrOpChTh, within the prognostic group of low, intermediate and high risk, and with criteria for anaplasia. The regressive/necrotic changes in total tumor mass of primary tumor and the proportion of epithelial, blastemal, and stromal components in the remaining viable tumor tissue were also determined. Cyclin A expression was evaluated by immunohistochemistry using a polyclonal rabbit, antihuman antibody (H-432). Results: Cyclin A overexpression was found in 34.3% of WTs, with higher frequency in tumors with epithelial (31.3%) and blastemal (37.1%) components than those with stromal component (17.7%). Regarding histological type, cyclin A overexpression was found most often in focal anaplasia (100%), stromal (60%), and diffuse anaplastic (66.7) WTs. The overexpression was also more frequent in stages 3 and 4 (77.8% and 66.7%, respectively) compared to tumors in stages 1 and 2 (13.3% and 12.5%, respectively; p = 0.004) in all components, as well as in blastemal component in stages 3 and 4 (77.8% and 66.7%, respectively) vs. stages 1 and 2 (13.3% and 25%, respectively, p = 0.009). Cyclin A overexpression in all components was 66.7% in WTs with metastasis and 31.3% in WTs without metastasis (p = 0.265, Fisher test). Log-rank testing revealed differences of OS regarding stage (p = 0.000), prognostic groups (p = 0.001), and cyclin A expression in blastemal component (p = 0.025). After univariate analysis, tumor stage (p = 0.001), prognostic group (p = 0.004), and cyclin A expression in blastemal component (p = 0.042) were significant prognostic factors for OS; however, after multivariate analysis, none of these factors were confirmed as independent predictors of survival. Discussion: This study showed that cyclin A overexpression might be associated with the development and progression of WT with anaplasia. Also, cyclin A overexpression was more often observed in advanced stages (3 and 4) of WT, in the group of high-risk WTs, and in focal and diffuse anaplasia WTs. There was no relation of cyclin A overexpression and metastatic ability of WT. Although this study has not confirmed the prognostic value of cyclin A overexpression, its association with unfavorable prognosis should be further evaluated. Copyright 2019 Radojevic-Škodric et al.
T2  - PeerJ
T1  - Immunohistochemical analysis of cyclin A expression in Wilms tumor
VL  - 6
IS  - 1
SP  - e6212
DO  - 10.7717/peerj.6212
ER  - 

@article{
author = "Radojević-Škodrić, Sanja and Brašanac, Dimitrije and Đuričić, Slaviša M. and Glumac, Sofija and Lončar, Zlatibor and Pavlović, Ivan and Todorović, Ana and Nikolić, Gorana V. and Baralić, Ivana and Pejić, Snežana",
year = "2019",
abstract = "Background: Cyclin A overexpression is found in a variety of human tumors and correlates with unfavorable outcome. We analyzed immunohistochemical expression of cyclin A in Wilms tumor (WT) in relation to clinicopathological characteristics, preoperative chemotherapy (PrOpChTh), and overall survival (OS). Methods: This retrospective study involved 43 patients who underwent nephrectomy from January 1996 to October 2010. Tumor stage and histological subtype were determined by revised Societé International d’Oncologie Pediatrique protocol, based on histological components/alterations caused by PrOpChTh, within the prognostic group of low, intermediate and high risk, and with criteria for anaplasia. The regressive/necrotic changes in total tumor mass of primary tumor and the proportion of epithelial, blastemal, and stromal components in the remaining viable tumor tissue were also determined. Cyclin A expression was evaluated by immunohistochemistry using a polyclonal rabbit, antihuman antibody (H-432). Results: Cyclin A overexpression was found in 34.3% of WTs, with higher frequency in tumors with epithelial (31.3%) and blastemal (37.1%) components than those with stromal component (17.7%). Regarding histological type, cyclin A overexpression was found most often in focal anaplasia (100%), stromal (60%), and diffuse anaplastic (66.7) WTs. The overexpression was also more frequent in stages 3 and 4 (77.8% and 66.7%, respectively) compared to tumors in stages 1 and 2 (13.3% and 12.5%, respectively; p = 0.004) in all components, as well as in blastemal component in stages 3 and 4 (77.8% and 66.7%, respectively) vs. stages 1 and 2 (13.3% and 25%, respectively, p = 0.009). Cyclin A overexpression in all components was 66.7% in WTs with metastasis and 31.3% in WTs without metastasis (p = 0.265, Fisher test). Log-rank testing revealed differences of OS regarding stage (p = 0.000), prognostic groups (p = 0.001), and cyclin A expression in blastemal component (p = 0.025). After univariate analysis, tumor stage (p = 0.001), prognostic group (p = 0.004), and cyclin A expression in blastemal component (p = 0.042) were significant prognostic factors for OS; however, after multivariate analysis, none of these factors were confirmed as independent predictors of survival. Discussion: This study showed that cyclin A overexpression might be associated with the development and progression of WT with anaplasia. Also, cyclin A overexpression was more often observed in advanced stages (3 and 4) of WT, in the group of high-risk WTs, and in focal and diffuse anaplasia WTs. There was no relation of cyclin A overexpression and metastatic ability of WT. Although this study has not confirmed the prognostic value of cyclin A overexpression, its association with unfavorable prognosis should be further evaluated. Copyright 2019 Radojevic-Škodric et al.",
journal = "PeerJ",
title = "Immunohistochemical analysis of cyclin A expression in Wilms tumor",
volume = "6",
number = "1",
pages = "e6212",
doi = "10.7717/peerj.6212"
}

Radojević-Škodrić, S., Brašanac, D., Đuričić, S. M., Glumac, S., Lončar, Z., Pavlović, I., Todorović, A., Nikolić, G. V., Baralić, I.,& Pejić, S.. (2019). Immunohistochemical analysis of cyclin A expression in Wilms tumor. in PeerJ, 6(1), e6212.
https://doi.org/10.7717/peerj.6212

Radojević-Škodrić S, Brašanac D, Đuričić SM, Glumac S, Lončar Z, Pavlović I, Todorović A, Nikolić GV, Baralić I, Pejić S. Immunohistochemical analysis of cyclin A expression in Wilms tumor. in PeerJ. 2019;6(1):e6212.
doi:10.7717/peerj.6212 .

Radojević-Škodrić, Sanja, Brašanac, Dimitrije, Đuričić, Slaviša M., Glumac, Sofija, Lončar, Zlatibor, Pavlović, Ivan, Todorović, Ana, Nikolić, Gorana V., Baralić, Ivana, Pejić, Snežana, "Immunohistochemical analysis of cyclin A expression in Wilms tumor" in PeerJ, 6, no. 1 (2019):e6212,
https://doi.org/10.7717/peerj.6212 . .

TY  - JOUR
AU  - Latić, Dragana
AU  - Pejić, Snežana
AU  - Savić, Slaviša
AU  - Lončar, Zlatibor
AU  - Nikolić, Ivan M.
AU  - Nikolić, Gorana V.
AU  - Pavlović, Ivan
AU  - Radojević-Škodrić, Sanja
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8078
AB  - Purpose: There is a need for identifying molecular prognostic biomarkers to better predict clinical outcomes in patients with renal cell carcinoma (RCC). This study investigated the pattern of cyclin D1 and p57 expression in RCC patients and evaluated their relation with clinicopathological characteristics and overall survival (OS). Methods: Immunohistochemistry was applied to paraffin-embedded tissue sections of 74 RCC patients. Two cut-off groups were defined by the fraction of positive cells as fol-lows: ≤10% and >10% positive cells for cyclin D1, and ≤5% and >5% positive cells for p57. Results: Cyclin D1 expression in >10% of positive cells was observed mostly in the clear cell RCC, while p57 expression in ≤5% of positive cells was found in 86% of chromophobe RCC specimens. The higher expression of cyclin D1 and lower expression of p57 were more frequent in grade I-II tumors. OS was associated with unfavorable clinicopathological characteristics. However, cyclin D1/p57 expression did not influence the survival rates. Conclusion: Although cyclin D1 and p57 expression did not affect survival rates in RCC patients, proper validation and establishment of the qualitative cut-off point are needed for these tumors.
T2  - Journal of BUON
T1  - Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma
VL  - 24
IS  - 1
SP  - 301
EP  - 309
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8078
ER  - 

@article{
author = "Latić, Dragana and Pejić, Snežana and Savić, Slaviša and Lončar, Zlatibor and Nikolić, Ivan M. and Nikolić, Gorana V. and Pavlović, Ivan and Radojević-Škodrić, Sanja",
year = "2019",
abstract = "Purpose: There is a need for identifying molecular prognostic biomarkers to better predict clinical outcomes in patients with renal cell carcinoma (RCC). This study investigated the pattern of cyclin D1 and p57 expression in RCC patients and evaluated their relation with clinicopathological characteristics and overall survival (OS). Methods: Immunohistochemistry was applied to paraffin-embedded tissue sections of 74 RCC patients. Two cut-off groups were defined by the fraction of positive cells as fol-lows: ≤10% and >10% positive cells for cyclin D1, and ≤5% and >5% positive cells for p57. Results: Cyclin D1 expression in >10% of positive cells was observed mostly in the clear cell RCC, while p57 expression in ≤5% of positive cells was found in 86% of chromophobe RCC specimens. The higher expression of cyclin D1 and lower expression of p57 were more frequent in grade I-II tumors. OS was associated with unfavorable clinicopathological characteristics. However, cyclin D1/p57 expression did not influence the survival rates. Conclusion: Although cyclin D1 and p57 expression did not affect survival rates in RCC patients, proper validation and establishment of the qualitative cut-off point are needed for these tumors.",
journal = "Journal of BUON",
title = "Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma",
volume = "24",
number = "1",
pages = "301-309",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8078"
}

Latić, D., Pejić, S., Savić, S., Lončar, Z., Nikolić, I. M., Nikolić, G. V., Pavlović, I.,& Radojević-Škodrić, S.. (2019). Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma. in Journal of BUON, 24(1), 301-309.
https://hdl.handle.net/21.15107/rcub_vinar_8078

Latić D, Pejić S, Savić S, Lončar Z, Nikolić IM, Nikolić GV, Pavlović I, Radojević-Škodrić S. Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma. in Journal of BUON. 2019;24(1):301-309.
https://hdl.handle.net/21.15107/rcub_vinar_8078 .

Latić, Dragana, Pejić, Snežana, Savić, Slaviša, Lončar, Zlatibor, Nikolić, Ivan M., Nikolić, Gorana V., Pavlović, Ivan, Radojević-Škodrić, Sanja, "Cyclin d1 and p57 expression in relation to clinicopathological characteristics and overall survival in patients with renal cell carcinoma" in Journal of BUON, 24, no. 1 (2019):301-309,
https://hdl.handle.net/21.15107/rcub_vinar_8078 .

TY  - JOUR
AU  - Lujić, Nenad
AU  - Sopta, Jelena
AU  - Kovačević, Relja
AU  - Stevanović, Vladan
AU  - Davidović, Radoslav S.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1298
AB  - To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and beta-catenin. Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p LT 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.
T2  - International Orthopaedics
T1  - Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67
VL  - 40
IS  - 11
SP  - 2393
EP  - 2399
DO  - 10.1007/s00264-016-3292-2
ER  - 

@article{
author = "Lujić, Nenad and Sopta, Jelena and Kovačević, Relja and Stevanović, Vladan and Davidović, Radoslav S.",
year = "2016",
abstract = "To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and beta-catenin. Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p LT 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.",
journal = "International Orthopaedics",
title = "Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67",
volume = "40",
number = "11",
pages = "2393-2399",
doi = "10.1007/s00264-016-3292-2"
}

Lujić, N., Sopta, J., Kovačević, R., Stevanović, V.,& Davidović, R. S.. (2016). Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67. in International Orthopaedics, 40(11), 2393-2399.
https://doi.org/10.1007/s00264-016-3292-2

Lujić N, Sopta J, Kovačević R, Stevanović V, Davidović RS. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67. in International Orthopaedics. 2016;40(11):2393-2399.
doi:10.1007/s00264-016-3292-2 .

Lujić, Nenad, Sopta, Jelena, Kovačević, Relja, Stevanović, Vladan, Davidović, Radoslav S., "Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67" in International Orthopaedics, 40, no. 11 (2016):2393-2399,
https://doi.org/10.1007/s00264-016-3292-2 . .

TY  - JOUR
AU  - Perović, Milan
AU  - Gojnic, Miroslava
AU  - Arsić, Biljana
AU  - Pantic, Igor
AU  - Stefanovic, Tomislav
AU  - Kovacevic, Gordana
AU  - Kovacevic, Milica
AU  - Garalejic, Eliana
AU  - Dugalic, Stefan
AU  - Radakovic, Jovana
AU  - Babic, Uros
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/603
AB  - BackgroundThe aim of the present study was to investigate the relationship between mid-trimester ultrasound fetal liver length (FLL) and gestational diabetes mellitus (GDM) in a high-risk population. MethodsA prospective study was performed in 331 women with singleton pregnancies who were at high risk of GDM and were undergoing a mid-trimester ultrasound examination. The ultrasound scan at 23 weeks gestation was followed by a 100-g oral glucose tolerance test (OGTT) at 24 weeks gestation. Correlations between FLL and OGTT results at different time points were tested. Receiver operating characteristic (ROC) analysis of FLL as a potential prognostic factor for GDM was also performed. ResultsIn GDM patients, there was a significant positive correlation (P LT 0.01) between FLL and OGTT glycemia immediately before and 60, 120, and 180min after glucose intake. Mean FLL in GDM was significantly higher than in healthy subjects (41.04 vs 31.09mm, respectively; P LT 0.001). When tested as a potential prognostic factor for GDM, fetal liver measurements showed excellent diagnostic performance. The ROC analysis established a cut-off value of FLL of 39mm for the prediction GDM, with sensitivity of 71.76%, specificity 97.56%, positive predictive value 91.0%, and negative predictive value 90.9%. The usefulness of FLL measurements was supported by a high area under the ROC curve (90.5%). ConclusionIn conclusion, there is a strong correlation between FLL and OGTT results, with FLL possibly serving as a valid marker for the prediction of GDM in high-risk populations.
T2  - Journal of Diabetes
T1  - Relationship between mid-trimester ultrasound fetal liver length measurements and gestational diabetes mellitus
VL  - 7
IS  - 4
SP  - 497
EP  - 505
DO  - 10.1111/1753-0407.12207
ER  - 

@article{
author = "Perović, Milan and Gojnic, Miroslava and Arsić, Biljana and Pantic, Igor and Stefanovic, Tomislav and Kovacevic, Gordana and Kovacevic, Milica and Garalejic, Eliana and Dugalic, Stefan and Radakovic, Jovana and Babic, Uros and Isenović, Esma R.",
year = "2015",
abstract = "BackgroundThe aim of the present study was to investigate the relationship between mid-trimester ultrasound fetal liver length (FLL) and gestational diabetes mellitus (GDM) in a high-risk population. MethodsA prospective study was performed in 331 women with singleton pregnancies who were at high risk of GDM and were undergoing a mid-trimester ultrasound examination. The ultrasound scan at 23 weeks gestation was followed by a 100-g oral glucose tolerance test (OGTT) at 24 weeks gestation. Correlations between FLL and OGTT results at different time points were tested. Receiver operating characteristic (ROC) analysis of FLL as a potential prognostic factor for GDM was also performed. ResultsIn GDM patients, there was a significant positive correlation (P LT 0.01) between FLL and OGTT glycemia immediately before and 60, 120, and 180min after glucose intake. Mean FLL in GDM was significantly higher than in healthy subjects (41.04 vs 31.09mm, respectively; P LT 0.001). When tested as a potential prognostic factor for GDM, fetal liver measurements showed excellent diagnostic performance. The ROC analysis established a cut-off value of FLL of 39mm for the prediction GDM, with sensitivity of 71.76%, specificity 97.56%, positive predictive value 91.0%, and negative predictive value 90.9%. The usefulness of FLL measurements was supported by a high area under the ROC curve (90.5%). ConclusionIn conclusion, there is a strong correlation between FLL and OGTT results, with FLL possibly serving as a valid marker for the prediction of GDM in high-risk populations.",
journal = "Journal of Diabetes",
title = "Relationship between mid-trimester ultrasound fetal liver length measurements and gestational diabetes mellitus",
volume = "7",
number = "4",
pages = "497-505",
doi = "10.1111/1753-0407.12207"
}

Perović, M., Gojnic, M., Arsić, B., Pantic, I., Stefanovic, T., Kovacevic, G., Kovacevic, M., Garalejic, E., Dugalic, S., Radakovic, J., Babic, U.,& Isenović, E. R.. (2015). Relationship between mid-trimester ultrasound fetal liver length measurements and gestational diabetes mellitus. in Journal of Diabetes, 7(4), 497-505.
https://doi.org/10.1111/1753-0407.12207

Perović M, Gojnic M, Arsić B, Pantic I, Stefanovic T, Kovacevic G, Kovacevic M, Garalejic E, Dugalic S, Radakovic J, Babic U, Isenović ER. Relationship between mid-trimester ultrasound fetal liver length measurements and gestational diabetes mellitus. in Journal of Diabetes. 2015;7(4):497-505.
doi:10.1111/1753-0407.12207 .

Perović, Milan, Gojnic, Miroslava, Arsić, Biljana, Pantic, Igor, Stefanovic, Tomislav, Kovacevic, Gordana, Kovacevic, Milica, Garalejic, Eliana, Dugalic, Stefan, Radakovic, Jovana, Babic, Uros, Isenović, Esma R., "Relationship between mid-trimester ultrasound fetal liver length measurements and gestational diabetes mellitus" in Journal of Diabetes, 7, no. 4 (2015):497-505,
https://doi.org/10.1111/1753-0407.12207 . .

TY  - JOUR
AU  - Davidović, Radoslav S.
AU  - Sopta, Jelena
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
AU  - Stanojevic, Maja
AU  - Tulic, Goran
AU  - Dimitrijević, Bogomir B.
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5646
AB  - Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.
T2  - Medical Oncology
T1  - p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0682-9
ER  - 

@article{
author = "Davidović, Radoslav S. and Sopta, Jelena and Mandušić, Vesna and Krajnović, Milena M. and Stanojevic, Maja and Tulic, Goran and Dimitrijević, Bogomir B.",
year = "2013",
abstract = "Liposarcoma represents the most frequent group of soft tissue sarcomas. The group can be divided into three different classes: (1) differentiated/undifferentiated (WDLPS/DDLPS), (2) myxoid/round cell (MLPS/RCLPS) and (3) pleomorphic liposarcoma (PLS). It has become apparent that p53-p14 and Rb-p16 pathways play important roles in the pathogenesis of various sarcoma types. Molecular studies of the genes involved in these two pathways showed wide variations between the liposarcoma subtypes or even within the same subtype. We sought to examine mutational status of p53 and methylation status of p16(INK4a)/p14(ARF) genes in primary and recurrent liposarcoma tumors. There were twelve myxoid (12/18, 66.7 %) and six pleomorphic liposarcoma (6/18, 33.3 %) samples. Immunohistochemical analysis revealed that p53 protein was overexpressed in 3/12 MLPS (25 %) and 6/6 PLS (100 %). Mutational analysis showed that 2/11 MLPS (18.2 %) and 2/6 PLS (33.3 %) contained mutated p53 gene. On the other hand, 3/18 samples (16.7 %) had methylated p16 promoter. However, the frequencies of the p14(ARF) gene methylation were 83.3 % (10/12) and 50 % (3/6) in myxoid and pleomorphic group, respectively. Overall, 15 out of 18 (83.3 %) samples had either p53 gene mutation or methylated p14(ARF) promoter. The results from the current study suggest significant impact of the p14(ARF) gene methylation on the pathogenesis and progression of myxoid and to a lesser extent pleomorphic liposarcoma. Despite the limited number of samples, our study points to necessity of further investigation of p53-p14 and Rb-p16 pathways in liposarcoma.",
journal = "Medical Oncology",
title = "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0682-9"
}

Davidović, R. S., Sopta, J., Mandušić, V., Krajnović, M. M., Stanojevic, M., Tulic, G.,& Dimitrijević, B. B.. (2013). p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. in Medical Oncology, 30(3).
https://doi.org/10.1007/s12032-013-0682-9

Davidović RS, Sopta J, Mandušić V, Krajnović MM, Stanojevic M, Tulic G, Dimitrijević BB. p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma. in Medical Oncology. 2013;30(3).
doi:10.1007/s12032-013-0682-9 .

Davidović, Radoslav S., Sopta, Jelena, Mandušić, Vesna, Krajnović, Milena M., Stanojevic, Maja, Tulic, Goran, Dimitrijević, Bogomir B., "p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma" in Medical Oncology, 30, no. 3 (2013),
https://doi.org/10.1007/s12032-013-0682-9 . .